Shares in Avita Medical were unchanged today despite receiving approval from the US Food and Drug Administration (FDA) to begin clinical trials of its ReCell Spray-On Skin device early next year, after the company suspended initial trials in 2008.
ECM driven by Business News' corporate finance database includes private equity relationships
Who are the leading hands in the West Australian M&A marketplace
| Label | Value |
|---|---|
| Rio Tinto | $26.13bn |
| BHP Billiton Iron Ore | $20.48bn |
| North West Shelf Venture | $14.92bn |
| Gold Corporation | $6.82bn |
| Fortescue Metals Group | $6.68bn |
| Others | $22.08bn |
© Copyright Business News 2013. You may share content using the tools provided but do not copy and redistribute.
